Komen announces $26 Million in Grants including $650,000 awarded to Kansas Researchers

SUSAN G. KOMEN ANNOUNCES $26 MILLION INVESTMENT IN NEW RESEARCH TO FIND SOLUTIONS FOR AGGRESSIVE AND METASTATIC BREAST CANCERS,
AND TO HELP COMMUNITIES MOST AT RISK

Kansas Researchers Receive $650,000 in Research Funding

DALLAS – Sept. 25, 2018 – Susan G. Komen®, the world’s leading breast cancer organization, today announced an additional investment of nearly $26 million to fund 62 new research projects that seek to answer some of the toughest questions facing breast cancer. This new funding is part of the organization’s efforts to reduce the number of breast cancer deaths in the U.S. by 50 percent by 2026 and brings its total research investment to $988 million to date – the largest nonprofit investment outside the U.S. government.

The grants include $650,000 in new funding for research at two institutions in Kansas, bringing Komen’s total research investment in Kansas to $10,942,251 since 1982.

“This year, Komen is investing in a number of areas that will help us achieve our bold goal and save lives. We are seeking answers to why our current drugs work for some patients, but not all, or why they work at first, but later become ineffective,” said Komen Chief Scientific Advisor, George Sledge, M.D., Chief of Oncology at Stanford University Department of Medicine. “We are also looking into aggressive forms of the disease like triple negative and inflammatory breast cancer, which tend to have poorer outcomes. By investigating novel techniques and therapies, we hope to bring new treatment options to patients.”

The newly announced grants will investigate critical areas in breast cancer research, including (but not limited to) projects focused on one or more of the following:

  • Drug Resistance and Metastasis (40 grants, representing 70 percent of the grants awarded)
  • Triple Negative Breast Cancer (23 grants)
  • New Treatments (38 grants) such as Immunotherapies (9 grants)
  • Health Disparities (8 grants)

This year, Komen’s competitive grant program for young investigators was entirely focused on drug resistance and metastatic disease. “Komen continues its long-standing investment in the next generation of scientists, to ensure that brilliant researchers whose careers are just beginning have funding to pursue their novel ideas,” said Komen Chief Scientific Advisor, Jennifer Pietenpol, Ph.D., Executive Vice President for Research and Director of the Vanderbilt-Ingram Cancer Center at Vanderbilt University Medical Center. “We are proud that this investment includes opportunities for 23 innovative and inspired researchers to lead the way in making breast cancer discoveries that will improve care for all and help save lives.”

“More than 41,000 women and men will lose their lives to breast cancer this year alone. I lost my mother to the disease a few years back, and I myself have been treated for aggressive triple negative breast cancer. The idea that it could impact my daughters is unacceptable,” said Komen President and CEO Paula Schneider. “We all have a personal reason or passion that we support the fight against breast cancer, and we’re proud to invite people to support the work that means the most to them. It will take all of us working together to save lives and ultimately end this disease.”

Komen’s Investments in Kansas

Komen’s research program is funded in part by contributions from Komen’s nationwide Network of Affiliates, which directs a portion of funds raised locally to Komen’s national research program, while also investing in vital community programs that serve local women and men facing breast cancer.

Since 1994, Komen Kansas City has funded $11,518,395 to community programs serving local women and men, while contributing $4,155,625 to Komen research (This is in addition to another nearly $5 million in programmatic support provided by the affiliate directly).

“We are extremely thankful for the friends, family, and communities that fight alongside us, helping to reduce the number of breast cancer deaths in Kansas and Missouri, both on the ground and through research, and especially research into the most lethal breast cancers,” said Michael A. Levine, Interim Executive Director. “As we gather thousands next week for our 25th Annual Race for the Cure we know that funds raised that day will be working to save the lives of the most vulnerable in our communities.”

In Kansas, Komen is granting to the following researchers:

Komen Scholar Danny Welch, Ph.D., from the University of Kansas Medical Center, will receive $200,000 to continue to study the role of genes that suppress the ability of breast cancer cells to spread to other parts of the body (metastasis). By understanding why and how metastasis happens, new targets can be identified for therapy and guide treatment decisions.

Xiaoqing Wu, Ph.D., from The University of Kansas Center for Research, will receive $450,000 to study a protein, HuR, which may contribute to chemotherapy resistance in triple negative breast cancer (TNBC). HuR is found at high levels in TNBC and is believed to help it grow and spread. Dr. Wu will determine if targeting HuR could overcome TNBC resistance to chemotherapy, and thus become a new treatment target for this aggressive cancer type.

Research has been a cornerstone of Komen’s work since opening its doors in 1982. Komen also works to inspire action through advocacy and public policy, to mobilize communities through support services and opportunities to make a local impact, and provide the care that patients need (including screening, diagnostics, treatment, and navigation).

About Susan G. Komen®

Susan G. Komen is the world’s largest breast cancer organization, funding more breast cancer research than any other nonprofit outside of the federal government while providing real-time help to those facing the disease. Komen has set a Bold Goal to reduce the current number of breast cancer deaths by 50 percent in the U.S. by 2026. Since its founding in 1982, Komen has funded more than $988 million in research and provided more than $2.2 billion in funding to screening, education, treatment and psychosocial support programs serving millions of people in more than 60 countries worldwide. Komen was founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life. That promise has become Komen’s promise to all people facing breast cancer. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at ww5.komen.org/social.

Grants are contingent upon signed and executed contracts with Komen.

About Susan G. Komen® Greater Kansas City

Komen Kansas City is working to better the lives of those facing breast cancer in the local community. Through events like the Komen Kansas City Race for the Cure® and Rock the Ribbon, Komen Kansas City has invested more than $21 million in breast health programs in their 17-county Kansas and Missouri service area and has helped contribute to the more than $988 million invested globally in researchFor more information, call 816.842.0410, visit komenkansascity.org or behindtheribbon.org. Connect with them on social media: Facebook, Twitter or Instagram.

# # #

Susan G. Komen Announces $31 Million in Research Grant Funding with Metastatic Focus

SUSAN G. KOMEN® ANNOUNCES $31 MILLION IN 2017 FUNDING FOR 98 NEW
BREAST CANCER RESEARCH GRANTS, WITH FOCUS ON AGGRESSIVE
AND METASTATIC CANCERS

University of Kansas Cancer Center Researcher Receive $300,000 in Funding

DALLAS – September 26, 2017 – Susan G. Komen, the world’s leading breast cancer organization, today announced 2017 research funding of $30.7 million for 98 research grants, with a focus on new treatments and understanding of the most lethal forms and stages of breast cancer. Komen funding to institutions in 27 states and 7 countries also includes research into new screening technologies, treatments for metastatic and aggressive types of breast cancer and disparities in breast cancer outcomes.

The grants include $300,000 in new funding for research at one institution in Kansas, The University of Kansas Cancer Center, bringing Komen’s total research investment in Kansas to more than $10.5 million since 1982.

“We are focused on new treatments, ways to overcome drug resistance in breast cancer patients, and a better understanding of how and why breast cancer spreads, so that we can better treat metastatic breast cancer or prevent it all together,” said Ellen Willmott, interim president and CEO of Susan G. Komen. “This focus on aggressive and metastatic disease is the foundation of our Bold Goal to reduce U.S. breast cancer deaths by 50% by 2026.”

Metastatic breast cancer – which is breast cancer that has spread to other parts of the body like the brain, liver, bones or lungs – is responsible for almost all of the nation’s 40,000 annual breast cancer deaths. More than 154,000 women are living with metastatic disease in the U.S. today. By targeting metastatic disease, Komen is hoping to reduce breast cancer deaths dramatically in the U.S.

This year’s funding also includes $17.6 million to early-career investigators. “Funding for early-career researchers ensures a continuum of breast cancer research, across generations, which is critical in a time of tightening federal research dollars,” Willmott said.

Komen’s 2017 portfolio includes*:

  • 37 grants expanding our knowledge of metastatic breast cancer and how to better treat it or prevent it;
  • 37 grants looking into novel treatments for aggressive types of breast cancer (specifically, triple negative, inflammatory breast cancer luminal B, and ER-positive recurrent breast cancer).
  • 59 grants focused on new therapies, including 10 for targeted therapies and 20 for drug development
  • 24 investigating drug resistance (why drugs stop working in some patients)
  • 9 on disparities in breast cancer outcomes and 2 involving Big Data

“We are so thankful for the friends, family and neighbors that fight alongside us, helping to reduce the number of breast cancer deaths in Missouri and Kansas, both on the ground and through research,” said Denise Wiese, Susan G. Komen Greater Kansas City Interim Executive Director.

Komen’s Investments in Kansas

Komen’s research program is funded in part by contributions from Komen’s nationwide Network of Affiliates, which directs 25% of funds raised locally to Komen’s national research program, while investing the remaining 75% into community outreach programs that serve local women and men facing breast cancer.

University of Kansas Cancer Center

Komen Scholar Danny Welch, Ph.D., will receive $300,000 to study the role of genes that suppress the ability of breast cancer cells to spread to other parts of the body (metastasis). By understanding why and how metastasis happens, new targets can be identified for therapy and guide treatment decisions.

These new funds bring Komen’s total research investment in breast cancer to more than $956 million since opening its doors in 1982, the largest of any nonprofit and second only to the U.S. government. In addition to research, Komen and its nationwide network of Affiliates serve women and men in thousands of communities. To date, more than $2.1 billion has been invested in community programs that provide education, screening and treatment support.

Kansas also has 3 ongoing grants, awarded in previous years.

About Susan G. Komen®
Susan G. Komen is the world’s largest breast cancer organization outside of the federal government, funding more breast cancer research than any other nonprofit while providing real-time help to those facing the disease. Since its founding in 1982, Komen has funded more than $956 million in research and provided more than $2.1 billion in funding to screening, education, treatment and psychosocial support programs. Komen has worked in more than 60 countries worldwide. Komen was founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at ww5.komen.org/social

About Susan G. Komen® and Komen Greater Kansas City
Komen Kansas City is working to better the lives of those facing breast cancer in the local community. Through events like the Race for the Cure®, Rock the Ribbon and the Pink Promise Conference, Komen Kansas City has invested more than $21 million in community breast health programs in our 17-county service area and has helped contribute to the more than $956 million invested globally in researchFor more information, Visit komenkansascity.orgbehindtheribbon.org or call 816.842.0410. Connect with us on social media: FacebookTwitter or Instagram.

Grants are contingent upon signed and executed contracts with Komen.

# # #